COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre

Background: real-world data on COVID-19 vaccine safety, immunogenicity and acceptance in adults with congenital heart disease (ACHD) are lacking. Methods: ACHD patients who were offered COVID-19 vaccination from January to June 2021 were included. Data on adverse events, on patients’ attitude toward...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Flavia Fusco, Giancarlo Scognamiglio, Assunta Merola, Anna Selvaggia Roma, Carmine Nicastro, Micaela Spatarella, Maurizio D'Abbraccio, Gabriella Di Mauro, Umberto Atripaldi, Lidia Atripaldi, Anna Correra, Michela Palma, Rosaria Barracano, Nunzia Borrelli, Annalisa Capuano, Berardo Sarubbi
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Adult congenital heart disease COVID-19 Vaccination Antibody response IgG antispike ACHD Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/1c1cf7fc4f6c4a89b9ba096a98c776d2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1c1cf7fc4f6c4a89b9ba096a98c776d2
record_format	dspace
spelling	oai:doaj.org-article:1c1cf7fc4f6c4a89b9ba096a98c776d22021-11-04T04:42:23ZCOVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre2666-668510.1016/j.ijcchd.2021.100266https://doaj.org/article/1c1cf7fc4f6c4a89b9ba096a98c776d22021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666668521001907https://doaj.org/toc/2666-6685Background: real-world data on COVID-19 vaccine safety, immunogenicity and acceptance in adults with congenital heart disease (ACHD) are lacking. Methods: ACHD patients who were offered COVID-19 vaccination from January to June 2021 were included. Data on adverse events, on patients’ attitude towards vaccination and antispike IgG titre were retrospectively collected. A group of healthy individuals with similar age and sex undergoing vaccination was included for comparison. Results: 208 patients followed in a single ACHD tertiary centre (33.3 [26–45] years, 54% male) received COVID-19 vaccine, 65% vaccinated at our institution: 199 (96%) received Pfizer–BioNTech BNT162b2 vaccine, 4 (2%) Moderna-1273 and 5 (2%) AstraZeneca–ChAdOx1. Median follow-up after vaccination was 79 [57–96] days. No major adverse event was reported and the incidence of minor events was not different between ACHD patients and the control group. One patient was diagnosed with acute pericarditis. There were two deaths unrelated to the vaccine during follow-up. Three (1.5%) vaccinated patients tested positive for COVID-19. Antispike IgG titre, available in 159 (76%) patients, was 1334 [600–3401] BAU/ml, not significantly different from the control group (p=0.2). One patient with Fontan failure was seronegative. Advanced physiological stage was associated with lower antibody response, independently from previous viral exposure (p<0.0001). Fourteen percent refused COVID-19 vaccination at our institution. However, 50% of vaccinated patients declared to have been influenced by the discussion with the ACHD cardiologist and 66% of those vaccinated in situ reported that undergoing COVID-19 vaccination at the ACHD centre made them feel safer. Conclusion: COVID-19 vaccines appear safe in ACHD with satisfactory immunogenicity. However, the most vulnerable patients showed lower antibody response. ACHD team may play a key role in vaccine acceptance.Flavia FuscoGiancarlo ScognamiglioAssunta MerolaAnna Selvaggia RomaCarmine NicastroMicaela SpatarellaMaurizio D'AbbraccioGabriella Di MauroUmberto AtripaldiLidia AtripaldiAnna CorreraMichela PalmaRosaria BarracanoNunzia BorrelliAnnalisa CapuanoBerardo SarubbiElsevierarticleAdult congenital heart diseaseCOVID-19VaccinationAntibody responseIgG antispikeACHDDiseases of the circulatory (Cardiovascular) systemRC666-701ENInternational Journal of Cardiology Congenital Heart Disease, Vol 6, Iss , Pp 100266- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Adult congenital heart disease COVID-19 Vaccination Antibody response IgG antispike ACHD Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Adult congenital heart disease COVID-19 Vaccination Antibody response IgG antispike ACHD Diseases of the circulatory (Cardiovascular) system RC666-701 Flavia Fusco Giancarlo Scognamiglio Assunta Merola Anna Selvaggia Roma Carmine Nicastro Micaela Spatarella Maurizio D'Abbraccio Gabriella Di Mauro Umberto Atripaldi Lidia Atripaldi Anna Correra Michela Palma Rosaria Barracano Nunzia Borrelli Annalisa Capuano Berardo Sarubbi COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
description	Background: real-world data on COVID-19 vaccine safety, immunogenicity and acceptance in adults with congenital heart disease (ACHD) are lacking. Methods: ACHD patients who were offered COVID-19 vaccination from January to June 2021 were included. Data on adverse events, on patients’ attitude towards vaccination and antispike IgG titre were retrospectively collected. A group of healthy individuals with similar age and sex undergoing vaccination was included for comparison. Results: 208 patients followed in a single ACHD tertiary centre (33.3 [26–45] years, 54% male) received COVID-19 vaccine, 65% vaccinated at our institution: 199 (96%) received Pfizer–BioNTech BNT162b2 vaccine, 4 (2%) Moderna-1273 and 5 (2%) AstraZeneca–ChAdOx1. Median follow-up after vaccination was 79 [57–96] days. No major adverse event was reported and the incidence of minor events was not different between ACHD patients and the control group. One patient was diagnosed with acute pericarditis. There were two deaths unrelated to the vaccine during follow-up. Three (1.5%) vaccinated patients tested positive for COVID-19. Antispike IgG titre, available in 159 (76%) patients, was 1334 [600–3401] BAU/ml, not significantly different from the control group (p=0.2). One patient with Fontan failure was seronegative. Advanced physiological stage was associated with lower antibody response, independently from previous viral exposure (p<0.0001). Fourteen percent refused COVID-19 vaccination at our institution. However, 50% of vaccinated patients declared to have been influenced by the discussion with the ACHD cardiologist and 66% of those vaccinated in situ reported that undergoing COVID-19 vaccination at the ACHD centre made them feel safer. Conclusion: COVID-19 vaccines appear safe in ACHD with satisfactory immunogenicity. However, the most vulnerable patients showed lower antibody response. ACHD team may play a key role in vaccine acceptance.
format	article
author	Flavia Fusco Giancarlo Scognamiglio Assunta Merola Anna Selvaggia Roma Carmine Nicastro Micaela Spatarella Maurizio D'Abbraccio Gabriella Di Mauro Umberto Atripaldi Lidia Atripaldi Anna Correra Michela Palma Rosaria Barracano Nunzia Borrelli Annalisa Capuano Berardo Sarubbi
author_facet	Flavia Fusco Giancarlo Scognamiglio Assunta Merola Anna Selvaggia Roma Carmine Nicastro Micaela Spatarella Maurizio D'Abbraccio Gabriella Di Mauro Umberto Atripaldi Lidia Atripaldi Anna Correra Michela Palma Rosaria Barracano Nunzia Borrelli Annalisa Capuano Berardo Sarubbi
author_sort	Flavia Fusco
title	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
title_short	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
title_full	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
title_fullStr	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
title_full_unstemmed	COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
title_sort	covid-19 vaccination in adults with congenital heart disease: real-world data from an italian tertiary centre
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/1c1cf7fc4f6c4a89b9ba096a98c776d2
work_keys_str_mv	AT flaviafusco covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT giancarloscognamiglio covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT assuntamerola covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT annaselvaggiaroma covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT carminenicastro covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT micaelaspatarella covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT mauriziodabbraccio covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT gabrielladimauro covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT umbertoatripaldi covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT lidiaatripaldi covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT annacorrera covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT michelapalma covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT rosariabarracano covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT nunziaborrelli covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT annalisacapuano covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre AT berardosarubbi covid19vaccinationinadultswithcongenitalheartdiseaserealworlddatafromanitaliantertiarycentre
_version_	1718445194998710272

COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre

Ejemplares similares